Our Products
Enhancing pharmaceutical products so that patients can experience therapeutic efficacy with fewer side effects and more convenient dosing is Depomed’s primary goal. To date, the company has advanced two products to market, each formulated with the company’s proprietary AcuForm™ delivery technology.
Glumetza® (metformin HCl extended release tablets)
Once-daily treatment for adults with type 2 diabetes
- Approved in the United States and Canada
- Available in 500 mg tablets
- Marketed by Biovail Corporation (Canada)
Proquin® XR (ciprofloxacin hydrochloride)
Once-daily treatment for uncomplicated urinary tract infections
- Approved in the United States; application under review in Sweden
- Available in 500 mg tablets (3-tablet blister pack, 30 and 50 count bottles)
- Marketed by Watson Pharmaceuticals (United States) and Madaus SRL (Europe, pending regulatory approval)
Full prescribing and safety information can be found at www.glumetzaxr.com and www.proquinxr.com.